Skip to Main Content

Paper Details

Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.
Nat Commun
46
2022
Author NameAffiliation
Robert Saddawi-Konefkauniversity of california san diego School of Medicine
Robert Saddawi-KonefkaMoores Cancer Center, university of california san diego
Robert Saddawi-KonefkaGleiberman Head and Neck Cancer Center, university of california san diego
Farhoud Farajiuniversity of california san diego School of Medicine
Farhoud FarajiMoores Cancer Center, university of california san diego
Farhoud FarajiGleiberman Head and Neck Cancer Center, university of california san diego
Michael M AllevatoMoores Cancer Center, university of california san diego
Zhiyong WangMoores Cancer Center, university of california san diego
Alfredo A MolinoloMoores Cancer Center, university of california san diego
Alfredo A MolinoloMoores Cancer Center, university of california san diego
Jill P MesirovMoores Cancer Center, university of california san diego
Jill P Mesirovuniversity of california san diego School of Medicine
Jill P MesirovMoores Cancer Center, university of california san diego
Jill P Mesirovuniversity of california san diego School of Medicine
Ezra E W CohenMoores Cancer Center, university of california san diego
Ezra E W CohenGleiberman Head and Neck Cancer Center, university of california san diego
Ezra E W Cohenuniversity of california san diego School of Medicine
Joseph A Califanouniversity of california san diego School of Medicine
Joseph A CalifanoMoores Cancer Center, university of california san diego
Joseph A CalifanoGleiberman Head and Neck Cancer Center, university of california san diego
Jorge Silvio GutkindMoores Cancer Center, university of california san diego
Jorge Silvio GutkindGleiberman Head and Neck Cancer Center, university of california san diego
Jorge Silvio Gutkinduniversity of california san diego
  • 1 - 23

Datasets